Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Diabetes, Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 11/11/2017 |
| Start Date: | September 30, 2017 |
| End Date: | December 31, 2017 |
This is an investigator-initiated, prospective, randomized, multicenter, parallel,
open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and
time-in-range on CGM download in patients with T1D. TI is an inhaled ultra-rapid-acting
insulin, approved by the FDA for use in patients with diabetes. This is a pilot, real-life
study where patients will continue their routine diabetes care and use post-meal correction
dosages as deemed necessary for normalizing PPBG as per the protocol.
This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The
patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized
into the NL arm will continue using their usual prandial insulin dose before meals. Patients
who are randomized into the TI arm will be instructed to dose before the meals and take
necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will
be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone
visits). There will be a 4-week treatment comparison between TI and NL and 1-week of
post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic
panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
All patients will use real-time CGM (Dexcom G5®, San Diego, CA), which will be provided at
the randomization visit for their day-to-day diabetes care. CGM data will be downloaded at
every clinic visit on a secured computer. The data will be analyzed after the study for
different primary and secondary end points. All patients will be allowed to keep the CGM
after the study is over for their day-to-day diabetes care.
open-label, pilot clinical trial evaluating the efficacy of TI for PPBG, PPGE, and
time-in-range on CGM download in patients with T1D. TI is an inhaled ultra-rapid-acting
insulin, approved by the FDA for use in patients with diabetes. This is a pilot, real-life
study where patients will continue their routine diabetes care and use post-meal correction
dosages as deemed necessary for normalizing PPBG as per the protocol.
This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The
patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized
into the NL arm will continue using their usual prandial insulin dose before meals. Patients
who are randomized into the TI arm will be instructed to dose before the meals and take
necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will
be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone
visits). There will be a 4-week treatment comparison between TI and NL and 1-week of
post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic
panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
All patients will use real-time CGM (Dexcom G5®, San Diego, CA), which will be provided at
the randomization visit for their day-to-day diabetes care. CGM data will be downloaded at
every clinic visit on a secured computer. The data will be analyzed after the study for
different primary and secondary end points. All patients will be allowed to keep the CGM
after the study is over for their day-to-day diabetes care.
Inclusion Criteria:
1. Signed informed consent before any study-related activities,
2. Male or female aged 18-70 years,
3. Type 1 diabetes mellitus (T1D) duration more than six months
4. Treatment with multiple daily injections (MDI) for at least three months before
screening visit; stable insulin dose for the last one month,
5. No use of any oral anti-diabetics, any other form of insulin other than mentioned in
the protocol, or any other type of injections such as glucagon-like-peptide-1 (GLP-1)
analogs, pramlintide or insulin/GLP-1 analog combinations,
6. A1c between 6.5 to 10%,
7. Willingness to routinely collect at least two blood glucose measurements per day
needed to calibrate the CGM. Beyond the calibrations, patients may use CGM for
necessary action without having to confirm with fingersticks self-monitoring blood
glucose (SMBG), as approved by the Food and Drug Administration (FDA),
8. BMI ≤35 kg/m2,
9. Ability and willingness to adhere to the protocol including clinical and phone visits
and 4-week-long CGM wear,
10. Using insulin glargine or insulin degludec as basal insulin,
11. Able to use and understand CGM data,
12. Willing to complete phone and clinic visits,
13. Patients who eat three main meals in a day (breakfast, lunch, and dinner),
14. Patients who use insulin-carb ratio for bolus,
15. Ability to speak, read, and write English, and
16. Patients prandial insulin need must be <18 units per meal
Exclusion Criteria:
1. Use of any other diabetic medication other than allowed in the protocol,
2. Pregnant or intention to become pregnant during the study, or not using adequate birth
control methods,
3. Severe unexplained hypoglycemia requiring emergency treatment in the previous three
months,
4. Use of systemic or inhaled corticosteroids,
5. History of hemoglobinopathies,
6. Diagnosis of anemia,
7. Post-renal transplantation, currently undergoing dialysis, creatinine >2.0 mg/dl or a
calculated creatinine clearance of <50 mL/min,
8. Advanced or unstable retinopathy needing laser procedure or vitrectomy,
9. History of pancreatitis,
10. Extensive skin changes/diseases that inhibit wearing a sensor on normal skin,
11. Known allergy to adhesives,
12. Known allergy to study medication,
13. Participation in another investigational study protocol within 30 days before
enrollment,
14. Known chronic obstructive pulmonary disease, pulmonary hypertension, asthma, pulmonary
fibrosis, or any chronic pulmonary infection, or any systemic disease that primarily
affects the lungs. History of any pulmonary nodule will be excluded to participate in
the study,
15. Active smokers,
16. Marijuana users,
17. Insulin pump users,
18. Using insulin detemir or NPH as basal insulin, and
19. Any other condition, as determined by the investigator, which could make the subject
unsuitable for the trial, impairs the subject's suitability for the trial, or impairs
the validity of the informed consent -
We found this trial at
1
site
Click here to add this to my saved trials
